smaller molecules and ultimately to CO 2 , water and urea (9) . Blood levels achieved after oral glucosamine are only 20% of those achieved with intravenous glucosamine. Serum glucosamine concentrations were approximately 0.04 mmol/L when they are not consuming supplemental glucosamine. Intravenous infusion of approximately 9.7 g of glucosamine produced steady state serum glucosamine concentrations of approximately 0.65 mmol/L. Infusion of 30.45 g of glucosamine produced steady state serum glucosamine concentrations of approximately 1.42 mmol/L. Intake of usual oral doses of glucosamine in humans would achieve serum levels of approximately 0.06 mmol/L.
The main objective of the present study was to compare bioavailability of two pharmaceutical alternative formulations of glucosamine sulfate. The two formulations are different in salt form and strength, test formulation contains KCl in strength of 500 mg while reference formulation contains NaCl in strength of 250 mg. The dosage of glucosamine sulfate 500 mg for both formulations were administered as a single dose to 24 healthy volunteers under a two-treatment, two-period and two-sequence crossover study design with a minimum of one-week washout period. 
Material and Method Glucosamine preparations

Volunteers
Twenty-four healthy Thai volunteers aged between 18-45 years with a body mass index between 18-24 kg/m 2 were recruited at Siriraj Clinical Research Center, Siriraj Hospital. After explaining the details and the purposes of the present study, all healthy volunteers provided written informed consents. They were non-smoking, non-alcoholic, and free from significant cardiac, hepatic, renal, gastrointestinal, and hematological diseases, as assessed by physical examination and the following laboratory investigations: complete blood count, BUN, creatinine, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, fasting blood sugar, serum electrolyte, and hepatitis B surface antigen.
Urine pregnancy tests were negative in all female volunteers. Volunteers did not have a history of allergy to glucosamine and/or its constituents and did not receive other medicines within 14 days before the first study drug administration.
Study design
Randomized, single dose, fasting, two-period, two-sequence, crossover study with at least a one-week washout period was conducted. Volunteers were allocated into two equal groups. Each volunteer was assigned to a particular study group using a pre-printed randomization table generated by Microsoft Excel. During each period, the volunteers were admitted to the Siriraj Clinical Research Center, Siriraj Hospital. After overnight fasting for at least 8 hours, they received a single dose of test formulation (500 mg capsule) or reference formulation (2 x 250 mg capsules) along with 240 ml of drinking water. Volunteers continued fasting for 2 and 4 h (water and food, respectively) after drug administration.
The subjects were closely observed to assess the adverse events. As test product containing KCl 2.18 mmol/500 mg, serum potassium was monitored at pre-dose, 12, and 24 h after test and reference products administration.
The present study was approved by the independent Ethics Committee of the Faculty of Medicine, Siriraj Hospital, Mahidol University prior to commencing and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guideline. All subjects were individually gave written informed consent prior to starting the study procedures.
Sample collection and glucosamine analysis
Ten ml of each blood sample was collected by catheterized venupuncture at forearms from each subject. Sodium heparinized vacutainer tubes were used for sample collection. Thirteen samples were collected: 0 (before the dosing), 5, 10, 15, 30, 80, 90 min and 2, 4, 6, 8, 12 and 24 h after administration. The blood samples were centrifuged. Then, the plasma fractions were collected and kept at -70°C until analysis.
Propranolol was used as an internal standard. Glucosamine was extracted by liquid-liquid extraction technique, using acetronitrile and triethylamine. All of organic phase was evaporated to dryness under nitrogen gas. The residual was re-dissolved and injected to LC-MS/MS. The mobile phase consisted of acetroni-trile and formic acid. The analytical equipment used included a HPLC device coupled with a mass selective detector. The multiple reaction monitoring (MRM) mode used the range from m/z transition 179.90 to 143.70 for glucosamine and from m/z transition 260.00 to 116.00 for internal standard. Validation of this method was performed as recommended by the USFDA. Calibration curve was linearity in the range of 0.1 to 10 μg/mL with r 2 = 0.998979 and the lower limit of quantification for the validated assay was 0.1 μg/ml. Mean recovery of extraction was 89.83-96.99% and 106.45% for glucosamine and internal standard, respectively. The intra-and inter-assay precision were 2.81%-13.80% and 5.08-9.26%, respectively. The percentage average of intra-and inter-assay recovery was between 88.20%-119.60% and 96.40%-108.00%, respectively. Stability of glucosamine in plasma during sample processing and 30 days storage in -70°C were within the acceptable range. Glucosamine level was calculated using MassLynx version 4.0.
Pharmacokinetic and statistical analysis
A non-compartmental pharmacokinetic model was used to determine the pharmacokinetic parameters of glucosamine. The pharmacokinetic parameters, i.e., AUC 0→t , AUC 0→∞ , C max , t max , t 1/2 were determined using WinNonlin edition version 3.1. Statistical comparisons between pharmacokinetic parameters of the two products were analyzed using two-way ANOVA with p < 0.05 for statistical significance to assess the effect of formulation, periods, sequence, subjects within sequence. The variation in estimation of terminal slope as can be seen in lamda_z or t 1/2 calculation (0.693/ lamda_z), the AUC 0→∞ might not be a good parameter to be compared. Moreover, the authors' first previous bioanalytical method was not sensitive enough to detect the concentration of glucosamine. There are many BQL data even also at baseline level. Thus, it may not be possible to obtain reliable AUC 0→∞ parameters. Thus, the authors did the statistical analysis for AUC 0→t instead. The 90 percent confidence intervals of the test/reference ratio of C max , and AUC 0→t using log trans-formed data were determined. The bioequivalence between the two formulations would be accepted if the 90 percent confidence intervals (CI) of the log transformed C max , and AUC 0→t of test fell within 80-125% of the original product (10, 11) .
Results and Discussion
Twenty-four volunteers (16 males, 8 females) completed the present study. Demographic characteristics of subjects between the two groups seemed similar and shown in Table 1 . The average plasma concentrations of at each time point from 24 Healthy Volunteers after administration of the reference and test product are tabulated in Table 2 . No significant difference was observed in any of the analyzed pharmacokinetic parameters ( Table 3 ). The geometric mean for test t 1/2 is 15.650 and that for reference is 23.231, which show less difference. Because the distribution of t 1/2 might not be a normal distribution, it may be better to use the geometric mean for more log-normal distribution. The generic formulation had C max at 0.99 μg/ml, t max at 1.42 h while the original formulation had C max at 1.12 μg/ml, t max at 2.00 h ( Table 1 ). Ninety percent CI of the mean ratios (generic/original) of the log transformed of the C max and AUC 0→t were 93.69% (ranged from 86.68%-113.32%) and 97.73% (ranged from 87.38%-112.62%), respectively. Since the 90% CI for C max and AUC 0→t fell within the predefined bioequivalence acceptance limits (80-125% of the innovator); the generic and original formulations were considered bioequivalent in terms of the rate and extent of absorption.
The plots of average plasma concentration of glucosamine (ng/ml; mean + SD) vs. time over the 24 h sampling period after oral administration of 500 mg of the test and reference capsules are presented in Fig. 1 . It was found that the plasma profiles of the glucosamine concentration of both formulations exhibited close similar patterns, which were nearly super imposable. The amounts of glucosamine in plasma at pre-dose were detected by the fact that glucosamine is a normal constituent of the extracellular matrix of mammalian Glucosamine was well tolerated. The clinical tolerability was good with both formulations. No serious adverse events were registered in the course of the trial. For effects of potassium contained in the test product, most of the subjects (87.50%) had normal level of serum potassium (3.5-5.0 mmol/L). Three subjects (12.50%) were reported to be abnormal serum potassium. Two subjects reported hypokalemia (one after taking the test and one after taking reference product) and another subject reported hyperkalemia (after taking the reference product). However, EKG was normal. Another adverse event found was palpitation (after taking the test product) but with no clinical significance. These events were determined not related to the study drug either test or reference products. These events were also reported to the 
